Japan plans to revise its guidelines on the drone delivery of medicines later this month, which would mark the first revision since they were established two years ago. Service providers are closely watching how they will be revised, with calls…
To read the full story
Related Article
- Ono to Ditch Foipan Development for COVID-19 as it Misses Goal in Japan PIII
June 14, 2021
- Ono Launches Japan PIII Study for Foipan for COVID-19
November 10, 2020
- Ono Drops ONO-5334 for COVID-19, Pursues Foipan Project
July 31, 2020
- Ono to Test Pancreatitis Med Foipan for COVID-19: President
May 13, 2020
- Ono’s FY2019 Sales Up 1.3% on Keytruda-Tied Royalties
May 13, 2020
- Ono Curbing Camostat Supplies after Drug Reported as Potential COVID-19 Hopeful
April 15, 2020
BUSINESS
- Takeda Puts Up 100 Billion Yen for New Plasma Therapy Facility in Japan
March 24, 2023
- Ono, Kasawaki-Based AI Platform Firm Tie Up on Antibody Drug Discovery
March 24, 2023
- Hutchmed’s Colorectal Cancer Med Logs Positive Data in Japanese Cohort: Takeda
March 24, 2023
- Ono, Macomics Ink Macrophage Drug Discovery Deal
March 24, 2023
- Opdivo Gets South Korea OK for 1st Line Esophageal Cancer
March 24, 2023
The healthcare supply chain in Japan, as in all major markets, consists of biopharmaceutical manufacturers selling to wholesalers who in turn sell to hospitals, clinics, and pharmacies, where the drugs are finally dispensed to patients. Each party ideally contributes value…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…